Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about finding an affordable source for KX 826 powder for hair loss treatment. One user mentions using it alongside dutasteride and minoxidil.

User reports 12-week progress with HIMS spray, Minoxidil, micro-needling, and biotin. Notable baby hairs on crown and temples, hoping for further improvement.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

A user shared their positive experience with hair regrowth using minoxidil, hormone replacement therapy, and cyproterone acetate during their male-to-female transition. Another user discussed their successful hair transplant after transitioning and using finasteride, highlighting the challenges of hair loss and regrowth during transition.

The user experienced significant hair regrowth using 1.25mg finasteride daily and 5% topical minoxidil nightly, with no major side effects or shedding. The progress is evident, especially around the temple area, and the user is hopeful for continued growth.

A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.

The conversation is about hair loss progress using treatments such as Dutasteride, topical minoxidil, and a 1.5mm roller.

The user has been treating hair loss for a year using Hims topical finasteride/minoxidil, derma stamping, and RU58841, with plans to continue and hopes for more significant results. They have noticed some small hair growth at the temples and will provide updates on their progress.

A user discusses a topical treatment combining Minoxidil, Betamethasone Valerate, Canrenone, Finasteride, and Dutasteride for hair loss. The treatment is RX-only and provided by a dermatologist.

The user is struggling with seborrheic dermatitis and plans to try ciclopirox olamine after finding ketoconazole too drying. They are also using finasteride daily.

The user experienced significant hair regrowth after 9 months of using finasteride, with minimal use of minoxidil. They reported no side effects and emphasized patience and consistency in their treatment routine.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

Winlevi (clascoterone) is discussed as a treatment for hormonal acne and seborrheic dermatitis due to its ability to block DHT and regulate sebum production. The post suggests that Winlevi could offer a novel approach for managing seborrheic dermatitis.

Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.

The user experienced hair improvement after six months of using 1mg oral finasteride, with some side effects like reduced libido and initial mood changes. They are considering adding oral minoxidil for further regrowth.

Availability of topical anti-androgens, especially RU58841, in Australia. Issues with customs seizures and lack of credible local sources.

A new hair loss treatment using dermal exosomes can restore up to 90% of lost hair in mice. Users discuss potential human trials and compare it to Minoxidil and Finasteride.

The user has been using a topical solution containing minoxidil and finasteride for 10 months but is not satisfied with the results, as there is no significant hair regrowth or thickening. They are questioning whether they are a non-responder or if they should continue the treatment longer.

The user is one month into their FUE treatment and has just undergone PRP treatment at American Mane in Miami. They plan to start using minoxidil and LLT, take xpecia with saw palmetto, and try Exosome from ExoScrt and PRP for better hair growth results.

User uses 1ml RU58841 with 5ml stemoxydine for scalp coverage. Wants to switch to pyrilutamide and asks about mixing it with other compounds.

A 31-year-old woman shared her 9-month progress using 5% minoxidil foam for hair loss, noting significant improvement after initial shedding and seeing regrowth by month 4. She also used ketoconazole shampoo and has been on spironolactone for acne, but did not use finasteride.

The user is using finasteride, minoxidil, ketoconazole, and vitamins/minerals for hair loss, and had a hair transplant with 2300 grafts. They are seeking opinions on future improvement, with one response suggesting a 10-20% improvement in the next 4-6 months.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

A 40-year-old shared their positive experience with a second hair transplant at HDC Cyprus, involving 4148 grafts and costing around 9,000 euros. They used oral minoxidil, Dutasteride, biotin, and vitamins to aid recovery and were pleased with the results.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The conversation is about the effectiveness of a hair loss treatment product containing 0.01% Latanoprost, with the user considering trying it as a vehicle for RU58841. The user questions whether the dosage is too low to be effective.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.